Trial Outcomes & Findings for Six Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly (NCT NCT00807365)

Results Overview

Recruitment status

TERMINATED

Study phase

PHASE2

Target enrollment

5 participants

Primary outcome timeframe

2 years

Results posted on

2017-04-27

Participant milestones
Measure	GHRH Growth Hormone-Releasing Hormone GHRH: GHRH administered subcutaneously at 2.0 mg/kg/dose bolus each night at 11:00 Post Meridian (PM), 1:00 Ante Meridian (AM), 3:00 AM, \& 5:00 AM for 6 months.
Overall Study STARTED	5
Overall Study COMPLETED	0
Overall Study NOT COMPLETED	5

Reasons for withdrawal
Measure	GHRH Growth Hormone-Releasing Hormone GHRH: GHRH administered subcutaneously at 2.0 mg/kg/dose bolus each night at 11:00 Post Meridian (PM), 1:00 Ante Meridian (AM), 3:00 AM, \& 5:00 AM for 6 months.
Overall Study Study Terminated	5

Six Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly

Baseline characteristics by cohort
Measure	GHRH n=5 Participants Growth Hormone-Releasing Hormone GHRH: GHRH administered subcutaneously at 2.0 mg/kg/dose bolus each night at 11:00 PM, 1:00 AM, 3:00 AM, \& 5:00 AM for 6 months.
Age, Categorical <=18 years	0 Participants n=5 Participants
Age, Categorical Between 18 and 65 years	0 Participants n=5 Participants
Age, Categorical >=65 years	5 Participants n=5 Participants
Sex: Female, Male Female	2 Participants n=5 Participants
Sex: Female, Male Male	3 Participants n=5 Participants
Region of Enrollment United States	5 participants n=5 Participants

Timeframe: 2 years

Population: Study terminated prior to collection of data

Outcome data not reported

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Adverse event data not reported

Adverse event data not reported

Johns Hopkins University

Phone: 4105506484